Stock LEGN LEGEND BIOTECH CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-15 pm EDT 		5-day change 1st Jan Change
45.76 USD +3.11% Intraday chart for Legend Biotech Corporation +0.09% -23.95%
May. 15 Legend Expects to Log Profit in 2026 MT
May. 14 HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Legend Expects to Log Profit in 2026
MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating
MT
Legend Biotech's Loss Narrows in Q1 as Revenue Surges
MT
RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating
MT
Sector Update: Health Care Stocks Decline Pre-Bell Monday
MT
Sector Update: Health Care
MT
Transcript : Legend Biotech Corporation, Q1 2024 Earnings Call, May 13, 2024
Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell
MT
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales
DJ
Stock Futures Rise Pre-Bell Ahead of Key Inflation Data; Asia, Europe Churn
MT
Legend Biotech : LEGN Q1 2024 Earnings Presentation
PU
Earnings Flash (LEGN) LEGEND BIOTECH CORPORATION Reports Q1 Revenue $94M
MT
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
BU
Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission
MT
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer
MT
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BU
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
CI
US FDA mandates label updates on CAR-T cancer therapies
RE
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. News Legend Biotech Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW